← Issue №17/ week of Oct 25, 2026/Hepatology

Clinical Risk Factors for Advanced Fibrosis in Pathology-Proven Steatotic Liver Disease: Emphasis on Nonelder Subjects.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology retrospective · n=223 · Oct 20, 2026 · J Gastro Hep · IF 3.5

Clinical Risk Factors for Advanced Fibrosis in Pathology-Proven Steatotic Liver Disease: Emphasis on Nonelder Subjects.

New evidenceMASLDepidemiologybiomarker
Clinical takeawayOlder age, alcohol, T2DM, chronic HBV and obesity flag SLD patients at higher fibrosis risk in an HBV-endemic population; score performance varied by age (NFS best overall, AUROC 0.724; FIB-4 best under 50) in this single-centre biopsy cohort.
What it foundOlder age (OR: 1.04), alcohol consumption (OR: 5.77), T2DM (OR: 2.13), chronic HBV infection (OR: 2.52), and obesity (OR: 2.64) were independent risk factors for advanced fibrosis in SLD patients. In nonelder patients, older age (OR: 1.10) and obesity (OR: 3.75) were significant. In the MASLD subgroup, older age (OR: 1.04), hypertension (OR: 2.31), T2DM (OR: 3.07), and chronic HBV infection (OR: 3.59) remained significant.
ContextThis study confirms known risk factors for advanced fibrosis in SLD and highlights their relevance in nonelder and MASLD patients, refining risk stratification in HBV-endemic populations.
Reinforcessuggested applicable standard· American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Manage diabetes in GI/hepatology patients by individualizing the A1c target to the population, in cirrhosis, A1c is unreliable because altered red blood cell turnover typically underestimates glycemia, so set glycemic goals using blood glucose monitoring and/or CGM rather than a fixed A1c cutoff, and in diabetic gastroparesis individualize the target rather than applying a universal cutoff; ≤7% pre-bariatric, <6.5% pre-conception, while screening all T2DM for MASLD with FIB-4, screening T1DM for concurrent celiac disease, and screening for diabetic gastroparesis when chronic nausea, early satiety, or postprandial fullness are present. Evaluate new-onset DM after age 50 without obesity for a pancreatic cancer differential, and coordinate peri-procedural medication holds and multidisciplinary endocrinology involvement.

American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149 · reviewed 2026-07-23 ↗
Huang CT … Liu CJ · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues